Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Atif Zaman.
NEJM Journal Watch | 2006
Atif Zaman
Risk estimates for mother-to-child transmission of hepatitis C virus (HCV) vary from 3% to 10%, but risk factors for transmission are poorly
NEJM Journal Watch | 2018
Atif Zaman
The relationship between platelet count and unprovoked major or minor bleeding risk in patients with cirrhosis is unclear.In a prospective,
NEJM Journal Watch | 2018
Atif Zaman
The majority of patients who receive oral antiviral therapy for chronic hepatitis B virus (HBV) infection will require long-term viral suppression,
NEJM Journal Watch | 2018
Atif Zaman
The degree of fibrosis is the key prognostic indicator in people with liver disease. Previous estimates of the prevalence of liver fibrosis among the
NEJM Journal Watch | 2018
Atif Zaman
The current recommended therapy for recurrent hepatitis C virus (HCV) infection after liver transplantation is a combination of direct-acting antiviral
NEJM Journal Watch | 2018
Atif Zaman
Studies demonstrate lower efficacy of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV) genotype 3–infected patients when cirrhosis is
NEJM Journal Watch | 2018
Atif Zaman
Sponsoring Organization: American College of Gastroenterology (ACG)Target Audience: Hepatologists, gastroenterologists, primary care
NEJM Journal Watch | 2018
Atif Zaman
Recent studies demonstrate that direct-acting antiviral agents (DAAs) are safe and effective at eradicating hepatitis C virus (HCV)–related
NEJM Journal Watch | 2018
Atif Zaman
Norfloxacin therapy has been investigated for its potential to prevent spontaneous bacterial peritonitis (SBP) and improve survival in patients with
NEJM Journal Watch | 2018
Atif Zaman
In a review article, researchers summarize recent advancements in the diagnosis, prognosis, and treatment of variceal hemorrhage in patients with